
|Articles|October 18, 2012
Low-dose SSRI formulation shows promise for vasomotor symptoms
A new formulation of a selective serotonin receptor inhibitor (SSRI)-low-dose mesylate of paroxetine (LDMP)-shows promise for reducing vasomotor symptoms of menopause, according to results of two studies presented at the North American Menopause Society (NAMS) conference.
Advertisement
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Deborah Anderson, PhD, calls for expanded contraception access
2
Contemporary OB/GYN week in review: alcohol use, cardiac rehabilitation, and more
3
High rates of misdiagnosis reported among perimenopausal women
4
Dual NK3/NK1 Receptor Antagonism for Vasomotor Symptoms
5
















